Clinical Trial Update: The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating camrelizumab plus lenvatinib with TACE for borderline resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Lenvatinib (lenvatinib)
• TACE

Snippet

Sponsor: Sichuan University | Conditions: Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN